Department of Pharmaceutics, School of Pharmacy & Shanghai Pudong Hospital, Fudan University, 201203, Shanghai, China.
Key Laboratory of Smart Drug Delivery, Ministry of Education, School of Pharmacy, Fudan University, 201203, Shanghai, China.
Nat Commun. 2023 Jan 26;14(1):435. doi: 10.1038/s41467-023-35957-8.
The limited benefits of immunotherapy against glioblastoma (GBM) is closely related to the paucity of T cells in brain tumor bed. Both systemic and local immunosuppression contribute to the deficiency of tumor-infiltrating T cells. However, the current studies focus heavily on the local immunosuppressive tumor microenvironment but not on the co-existence of systemic immunosuppression. Here, we develop a nanostructure named Nano-reshaper to co-encapsulate lymphopenia alleviating agent cannabidiol and lymphocyte recruiting cytokine LIGHT. The results show that Nano-reshaper increases the number of systemic T cells and improves local T-cell recruitment condition, thus greatly increasing T-cell infiltration. When combined with immune checkpoint inhibitor, this therapeutic modality achieves 83.3% long-term survivors without recurrence in GBM models in male mice. Collectively, this work unveils that simultaneous reprogramming of systemic and local immune function is critical for T-cell based immunotherapy and provides a clinically translatable option for combating brain tumors.
免疫疗法治疗胶质母细胞瘤(GBM)的获益有限,这与脑肿瘤床中 T 细胞数量较少密切相关。全身性和局部免疫抑制均导致肿瘤浸润性 T 细胞的缺乏。然而,目前的研究主要集中在局部免疫抑制性肿瘤微环境上,而没有关注全身性免疫抑制的共存。在这里,我们开发了一种名为 Nano-reshaper 的纳米结构,用于共包封淋巴细胞减少缓解剂大麻二酚和淋巴细胞募集细胞因子 LIGHT。结果表明,Nano-reshaper 增加了系统 T 细胞的数量,并改善了局部 T 细胞募集条件,从而大大增加了 T 细胞浸润。当与免疫检查点抑制剂联合使用时,这种治疗方式在雄性小鼠的 GBM 模型中实现了 83.3%的长期无复发幸存者。总的来说,这项工作揭示了同时重塑系统和局部免疫功能对于基于 T 细胞的免疫疗法至关重要,并为对抗脑肿瘤提供了一种具有临床转化潜力的选择。
Cancer Lett. 2021-1-1
Front Immunol. 2022
J Neurooncol. 2021-2
Adv Exp Med Biol. 2023
Int J Nanomedicine. 2025-8-4
Pharmacol Res Perspect. 2025-8
Neurooncol Adv. 2025-6-24
Explor Target Antitumor Ther. 2025-2-24
J Neurooncol. 2025-2
Adv Drug Deliv Rev. 2022-3
Eur J Cancer. 2022-2
Front Oncol. 2021-10-28
Adv Drug Deliv Rev. 2021-12
Nat Commun. 2021-6-8
Nat Rev Cancer. 2021-6